US2014272100A1PendingUtilityA1

Processes for coating a carrier with microparticles

Assignee: TEVA PHARMAPriority: Jan 26, 2009Filed: May 27, 2014Published: Sep 18, 2014
Est. expiryJan 26, 2029(~2.5 yrs left)· nominal 20-yr term from priority
A61K 9/16A61K 9/167A61K 47/38A61K 31/41A61K 9/5089A61K 47/36A61K 9/5078
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Processes for coating a carrier with microparticles of a drug are described. For example, a coated carrier can be obtained in a one-stage process that entails evaporating a solvent from microdroplets of a solution containing an API to obtain dry microparticles, which are then coated on the carrier.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A process comprising the steps of:
 (a) providing a conveying gas carrying microdroplets of a solution comprising an active pharmaceutical ingredient and a solvent;   (b) evaporating the solvent from the microdroplets to obtain at least partially dried microparticles comprising the active pharmaceutical ingredient carried by the conveying gas; and   (c) contacting the at least partially dried microparticles comprising the active pharmaceutical ingredient carried by the conveying gas with a carrier bed to obtain a carrier coated with microparticles,   wherein the carrier bed is a static carrier bed or a periodically agitated carrier bed.   
     
     
         2 . The process of  claim 1 , wherein the active pharmaceutical ingredient is selected from the group consisting of: docetaxel, risperidone, beclomethasone, fluticasone, budesonide, salbutamol, terbutaline, ipratropium, oxitropium, formoterol, salmeterol, valsartan, ezetimibe, paliperidone, aprepitant, tacrolimus, sirolimus, everolimus and tiotropium. 
     
     
         3 . The process of  claim 1 , wherein the carrier is selected from the group consisting of: microcrystalline cellulose, lactose, and mannitol. 
     
     
         4 . The process of  claim 1 , wherein the microparticles have an average diameter of about 100 nm to about 10,000 nm. 
     
     
         5 . The process of  claim 4 , wherein the microparticles have an average diameter of about 200 nm to about 5,000 nm. 
     
     
         6 . The process of  claim 5 , wherein the microparticles have an average diameter of about 500 nm to about 5,000 nm. 
     
     
         7 . The process of  claim 6 , wherein the microparticles have an average diameter of about 500 nm to about 1,000 nm. 
     
     
         8 . The process of  claim 1 , wherein the solvent is ethanol. 
     
     
         9 . A process comprising the steps of:
 (a) providing a conveying gas carrying microdroplets of a solution of an active pharmaceutical ingredient and a solvent;   (b) evaporating the solvent from the microdroplets to obtain at least partially dried microparticles of the active pharmaceutical ingredient carried by the conveying gas; and   (c) coating a carrier with the at least partially dried microparticles of the active pharmaceutical ingredient carried by the conveying gas.   
     
     
         10 . The process of  claim 9 , wherein the carrier is selected from the group consisting of: microcrystalline cellulose, lactose, and mannitol. 
     
     
         11 . The process of  claim 9 , wherein the microdroplets have an average diameter of about 1 to about 15 micrometers. 
     
     
         12 . The process of  claim 9 , wherein the microparticles have an average diameter of about 100 nm to about 10,000 nm. 
     
     
         13 . The process of  claim 12 , wherein the microparticles have an average diameter of about 200 nm to about 5,000 nm. 
     
     
         14 . The process of  claim 13 , wherein the microparticles have an average diameter of about 500 nm to about 5,000 nm. 
     
     
         15 . The process of  claim 14 , wherein the microparticles have an average diameter of about 500 nm to about 1,000 nm. 
     
     
         16 . The process of  claim 9 , wherein the coating step comprises contacting the microparticles with a carrier bed to obtain a carrier coated with microparticles. 
     
     
         17 . The process of  claim 9 , wherein the active pharmaceutical ingredient is selected from the group consisting of: docetaxel, risperidone, beclomethasone, fluticasone, budesonide, salbutamol, terbutaline, ipratropium, oxitropium, formoterol, salmeterol, valsartan, ezetimibe, paliperidone, aprepitant, tacrolimus, sirolimus, everolimus and tiotropium. 
     
     
         18 . The process of  claim 9 , wherein the solvent is ethanol. 
     
     
         19 . The process of  claim 1 , wherein the evaporating step comprises completely evaporating the solvent from the microparticles such that the microparticles are dry when coated on the carrier. 
     
     
         20 . The process of  claim 9 , wherein the evaporating step comprises completely evaporating the solvent from the microparticles such that the microparticles are dry when coated on the carrier. 
     
     
         21 . The process of  claim 1 , wherein the process is a one stage process. 
     
     
         22 . The process of  claim 9 , wherein the process is a one stage process. 
     
     
         23 . The process of  claim 1  further comprising applying vacuum to the down-stream side of the carrier bed to provide laminar flow to the conveying gas. 
     
     
         24 . The process of  claim 9  further comprising applying vacuum to the down-stream side of the carrier bed to provide laminar flow to the conveying gas.

Join the waitlist — get patent alerts

Track US2014272100A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.